My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 372

    1.

    Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes.

    Natali A, Baldeweg S, Toschi E, Capaldo B, Barbaro D, Gastaldelli A, Yudkin JS, Ferrannini E.

    Diabetes Care. 2004 Jun;27(6):1349-57.PMID: 15161787 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

    Fonseca V, Rosenstock J, Patwardhan R, Salzman A.

    JAMA. 2000 Apr 5;283(13):1695-702. Erratum in: JAMA 2000 Sep 20;284(11):1384. PMID: 10755495 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.

    Derosa G, Cicero AF, Gaddi AV, Ciccarelli L, Piccinni MN, Salvadeo S, Pricolo F, Fogari E, Ghelfi M, Ferrari I, Fogari R.

    Clin Ther. 2005 Sep;27(9):1383-91.PMID: 16291411 [PubMed - indexed for MEDLINE]Related articles

    4.

    Effects of metformin and rosiglitazone monotherapy on insulin-mediated hepatic glucose uptake and their relation to visceral fat in type 2 diabetes.

    Iozzo P, Hallsten K, Oikonen V, Virtanen KA, Parkkola R, Kemppainen J, Solin O, Lonnqvist F, Ferrannini E, Knuuti J, Nuutila P.

    Diabetes Care. 2003 Jul;26(7):2069-74.PMID: 12832315 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

    Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.

    J Clin Pharm Ther. 2006 Aug;31(4):375-83.PMID: 16882108 [PubMed - indexed for MEDLINE]Related articles

    6.

    Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.

    Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G.

    Diabetes Care. 2006 Mar;29(3):554-9.PMID: 16505505 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.

    Roberts VL, Stewart J, Issa M, Lake B, Melis R.

    Clin Ther. 2005 Oct;27(10):1535-47.PMID: 16330290 [PubMed - indexed for MEDLINE]Related articles

    8.

    The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.

    Robinson AC, Burke J, Robinson S, Johnston DG, Elkeles RS.

    Diabetes Care. 1998 May;21(5):701-5.PMID: 9589227 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome.

    Derosa G, Gaddi AV, Piccinni MN, Ciccarelli L, Salvadeo S, Peros E, Ghelfi M, Ferrari I, Cicero AF.

    Pharmacotherapy. 2005 May;25(5):637-45.PMID: 15899724 [PubMed - indexed for MEDLINE]Related articles

    10.

    Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study.

    Bailey CJ, Bagdonas A, Rubes J, McMorn SO, Donaldson J, Biswas N, Stewart MW.

    Clin Ther. 2005 Oct;27(10):1548-61.PMID: 16330291 [PubMed - indexed for MEDLINE]Related articles

    11.

    In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control.

    Pistrosch F, Passauer J, Fischer S, Fuecker K, Hanefeld M, Gross P.

    Diabetes Care. 2004 Feb;27(2):484-90.PMID: 14747233 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial.

    Derosa G, Gaddi AV, Piccinni MN, Salvadeo S, Ciccarelli L, Fogari E, Ghelfi M, Ferrari I, Cicero AF.

    Diabetes Obes Metab. 2006 Mar;8(2):197-205.PMID: 16448524 [PubMed - indexed for MEDLINE]Related articles

    13.

    Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.

    Triplitt C, Glass L, Miyazaki Y, Wajcberg E, Gastaldelli A, De Filippis E, Cersosimo E, DeFronzo RA.

    Diabetes Care. 2006 Nov;29(11):2371-7.PMID: 17065670 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.

    Robbins DC, Beisswenger PJ, Ceriello A, Goldberg RB, Moses RG, Pagkalos EM, Milicevic Z, Jones CA, Sarwat S, Tan MH.

    Clin Ther. 2007 Nov;29(11):2349-64.PMID: 18158076 [PubMed - indexed for MEDLINE]Related articles

    15.

    Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes.

    Hällsten K, Virtanen KA, Lönnqvist F, Sipilä H, Oksanen A, Viljanen T, Rönnemaa T, Viikari J, Knuuti J, Nuutila P.

    Diabetes. 2002 Dec;51(12):3479-85.PMID: 12453903 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial.

    Dailey GE 3rd, Noor MA, Park JS, Bruce S, Fiedorek FT.

    Am J Med. 2004 Feb 15;116(4):223-9.PMID: 14969649 [PubMed - indexed for MEDLINE]Related articles

    17.

    Reductions in biomarkers of cardiovascular risk in type 2 diabetes with rosiglitazone added to metformin compared with dose escalation of metformin: an EMPIRE trial sub-study.

    Goldstein BJ, Weissman PN, Wooddell MJ, Waterhouse BR, Cobitz AR.

    Curr Med Res Opin. 2006 Sep;22(9):1715-23.PMID: 16968575 [PubMed - indexed for MEDLINE]Related articles

    18.

    Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus.

    Cusi K, Consoli A, DeFronzo RA.

    J Clin Endocrinol Metab. 1996 Nov;81(11):4059-67.PMID: 8923861 [PubMed - indexed for MEDLINE]Related articles

    19.

    One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes.

    Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH; QUARTET Study Group.

    Diabetes Care. 2004 Jan;27(1):141-7.PMID: 14693980 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.

    Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.

    Clin Ther. 2006 May;28(5):679-88. Erratum in: Clin Ther. 2006 Sep;28(9):1483. PMID: 16861090 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity